Alzamend Neuro

ALZN

시가총액 US$627만

Alzamend Neuro (ALZN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026   in Washington, DC Presentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial ATLANTA, Aug. 20, 2026 /PRNewswire/ -- Alzamend Neuro, Inc.  (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting resting-state functional magnetic resonance imaging ("fMRI") findings for AL001, Alzamend's novel organic lithium salt, has been accepted for poster presentation at Neuroscience 2026, the annual meeting of the Society for Neuroscience ("SfN"), to be held November 14–18, 2026 in Washington, DC. The abstract, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," will be presented as a poster in the Neuropsychiatric Disorders session (Session PSTR337) on Wednesday, November 18, 2026, from 8:00 a.m.

ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026   at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain Presentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001, Alzamend's novel organic lithium drug candidate, in healthy human subjects ATLANTA, Aug. 18, 2026 /PRNewswire/ -- Alzamend Neuro, Inc.  (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting pharmacokinetic imaging data for AL001, Alzamend's novel organic lithium salt, has been accepted for oral presentation at the International Society for Magnetic Resonance in Medicine ("ISMRM") Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR, to be held from September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain. The abstract, titled "Pharmacokinetics Imaging of Lithium at 7T – Results from a Phase 1/2A Clinical Trial with a Novel Organic Lithium Salt" (Abstract #00047), was selected following a competitive review by the workshop's organizing committee and will be presented in the "Proffered Papers" oral session on Tuesday, September 29, 2026 at 1:35 PM local time.

Company received $7.5 million in gross proceeds from the initial tranche of Series D Convertible Preferred Stock Agreement provides for up to $17.5 million in additional funding through subsequent tranche closings to support Alzamend's clinical programs and working capital needs ATLANTA, Aug. 4, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announced today that it has entered into a Securities Purchase Agreement (the "Agreement") with Ault Lending, LLC ("Ault Lending"), pursuant to which Ault Lending has agreed to purchase up to $25,000,000 of the Company's newly designated Series D Convertible Preferred Stock (the "Preferred Shares"), and closed on the initial tranche in the amount of $7.5 million. Under the terms of the Agreement, Ault Lending agreed to purchase up to 25,000 Preferred Shares at a purchase price of $1,000 per share, for an aggregate purchase price of $25,000,000, with each Preferred Share having a stated value of $1,050.

Potentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonate Expected Trends for Myo-Inositol Reduction : Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of action Potentially Preserved Glutamate Balance: Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may suggest better long-term tolerability ATLANTA, April 7, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced encouraging pharmacodynamic findings from a brain magnetic resonance spectroscopy ("MRS") analysis conducted in healthy human subjects (N=6) in a trial conducted at Massachusetts General Hospital. The study assessed changes in five key brain metabolites across 18 brain regions when participants received two-weeks of blood bioequivalent and lithium-dose equivalent AL001 or lithium carbonate relative to baseline.

Bioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonate Superior Brain Penetration: AL001 showed numerically higher lithium concentrations in all measured brain regions , including whole brain Faster Brain Uptake: AL001 reached peak brain concentration in 6.7 hours vs.

Head-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type 1 patients Topline data expected in third quarter of 2026 Topline data from the clinically completed "lithium in brain" imaging study in healthy subjects expected by the end of March 2026 ATLANTA, March 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the initiation of its Phase II clinical trial evaluating AL001 in patients diagnosed with BD type 1. The trial is being conducted at Massachusetts General Hospital ("MGH") and represents a significant step toward advancement of AL001 as a potentially safer and more effective lithium-based therapy.

Topline data expected in first quarter of 2026 Head-to-head studies of AL001 versus a marketed lithium carbonate product was conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA , Nov. 19, 2025 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced completion of the clinical portion of its first Phase II clinical study of AL001, in healthy human subjects. In collaboration with Massachusetts General Hospital as the clinical trial site, Alzamend is investigating the distinctive characteristics of AL001.

Session Topic is the I nnovation and Current Directions in Military Suicide Prevention, Research, and Programs Presentation Title is Quantitate Differences in Lithium Brain-to-Plasma Exposure in PTSD Subjects Between AL001 and Lithium Carbonate ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced it will have a poster presentation at the Military Health System Research Symposium (“MHSRS”), being held from August 4-7, 2025, in Orlando, Florida. “Our upcoming poster presentation at MHSRS 2025 represents an exceptional opportunity to spotlight our cutting-edge innovation and its transformative potential for active-duty service members and military veterans,” said Stephan Jackman, Chief Executive Officer of Alzamend.

During the year ended April 30, 2025, net cash provided by financing activities was $10.4 million Stockholder equity of $4.0 million at April 30, 2025, including $3.9 million of cash In May 2025, Alzamend dosed the first patient for the healthy human patients for the AL001 “Lithium in Brain” Studies at Massachusetts General Hospital In June 2025, Alzamend completed the final closing of its $5 million private placement months ahead of schedule ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), reported its financial results for the year ended April 30, 2025, which were disclosed on an annual report on Form 10-K filed on July 22, 2025, with the Securities and Exchange Commission. Alzamend has strengthened its financial position, reflecting a strategic focus on fiscal prudence and effective capital management.